IUVER
IUVER MEDICA RX Cream
In this formula, IUVER translates its melatonin-based dermo cosmetic expertise into a formulation conceived for skin stressed by radiotherapy. Instead of addressing dryness alone, the formula’s multi-pathway strategy combines antioxidant support, hydration, lipid replenishment, and barrier care. Melatonin forms the antioxidant core of the formula, complemented by tocopherol, while a lipid system with linolenic acid, oleic acid, palmitic acid, lecithin, and olive-derived lipids provides emollient and lipid-replenishing care. And betaine, glycerin, propylene glycol, and propanediol provide hydration and skin-conditioning support. The formulation addresses multiple needs associated with radiotherapy-stressed skin, including oxidative stress, dehydration, lipid depletion, barrier impairment, dryness, and discomfort. The cream is currently undergoing a hospital-based clinical trial in the context of radiotherapy-exposed skin, with the goal of bridging advanced dermo cosmetic science with clinical research in supportive oncology skin care.
Hall (Pavilion) and Stand Number: 1E-D3F
This product is a finalist in the category 个人护理 & 身体护理产品 of Cosmoprof Asia 2026
Launch Date (First worldwide launch must have been launched within 12 months prior to the event)
Planned Worldwide Launch: November 2026 Current status: Pre-launch — not yet commercially available. RX Cream is currently undergoing clinical evaluation prior to its commercial launch.
Retail Price & Fill Sizes
Retail Price & Fill Size Retail Price: Not yet commercially available — RRP to be confirmed. Fill Size: 100 ml
Product Description (Function, Benefits, and Target Consumer)
In this formula, IUVER translates its melatonin-based dermo cosmetic expertise into a formulation conceived for skin stressed by radiotherapy. Instead of addressing dryness alone, the formula’s multi-pathway strategy combines antioxidant support, hydration, lipid replenishment, and barrier care. Melatonin forms the antioxidant core of the formula, complemented by tocopherol, while a lipid system with linolenic acid, oleic acid, palmitic acid, lecithin, and olive-derived lipids provides emollient and lipid-replenishing care. And betaine, glycerin, propylene glycol, and propanediol provide hydration and skin-conditioning support. The formulation addresses multiple needs associated with radiotherapy-stressed skin, including oxidative stress, dehydration, lipid depletion, barrier impairment, dryness, and discomfort. The cream is currently undergoing a hospital-based clinical trial in the context of radiotherapy-exposed skin, with the goal of bridging advanced dermo cosmetic science with clinical research in supportive oncology skin care.
Product Innovation
RX Cream translates IUVER’s expertise in melatonin-based dermocosmetics into a formulation specifically conceived for radiotherapy-stressed skin. Rather than addressing dryness alone, its multi-pathway strategy combines antioxidant support, hydration, lipid replenishment and barrier care. Melatonin is complemented by essential fatty acids, olive-derived lipids, betaine, glycerin and tocopherol to address multiple needs of highly compromised skin simultaneously. Its innovation extends beyond formulation: RX Cream combines independently demonstrated skin compatibility with an ongoing hospital-based clinical trial, bridging advanced dermocosmetic science with clinical research in supportive oncology skincare.
Research, Clinical Tests & Trials Results (Safety & Dermatological)
Independent Dermatological Safety Study — AITEX
IUVER MEDICA RX Cream underwent an independent dermatological safety study conducted by AITEX to evaluate skin compatibility.
The formulation was assessed following a single application under an occlusive patch for 48 hours combined with Tape Stripping, a technique described in the study as providing greater sensitivity than a conventional patch test. The assessment was performed under dermatologist supervision. TAPE STRIP SERUM MEDICA 2025lp0…
10 volunteers with sensitive skin, aged 18–65 years, male and female, with Fitzpatrick phototypes I–III, completed the study. TAPE STRIP SERUM MEDICA 2025lp0…
All 10 volunteers showed a negative reaction, with no doubtful, weak, strong or extreme reactions recorded. The resulting Irritation Index (IR) was 0.0. TAPE STRIP SERUM MEDICA 2025lp0…
Under the AITEX classification system, IR=0 corresponds to NON-IRRITATING and VERY GOOD SKIN COMPATIBILITY. AITEX concluded that the tested formulation demonstrated VERY GOOD SKIN COMPATIBILITY and may carry the claim “dermatologically tested.” TAPE STRIP SERUM MEDICA 2025lp0… TAPE STRIP SERUM MEDICA 2025lp0…
Ongoing Clinical Trial
RX Cream is currently undergoing a clinical trial at Hospital General Universitario de Valencia in the context of skin exposed to radiotherapy. As the study is ongoing, no preliminary or final efficacy results are claimed at this stage.
Top 3 evidence points:
- Irritation Index: 0.0 — NON-IRRITATING.
- VERY GOOD SKIN COMPATIBILITY in sensitive skin under 48-hour occlusion + Tape Stripping.
- Currently undergoing hospital-based clinical evaluation in the context of radiotherapy-exposed skin
Product Claims, Benefits, Performance & Consumer Experience
Specifically developed for skin undergoing or recovering from radiotherapy.
Conceived around the particular skincare needs of oncology patients.
Provides antioxidant support to highly compromised skin.
Helps support and maintain skin barrier integrity.
Provides intensive hydration and lipid-replenishing care.
Helps relieve sensations associated with dryness, tightness and discomfort.
Provides emollient care for vulnerable skin.
Melatonin-centered antioxidant strategy.
Essential fatty acids and olive-derived lipids provide complementary lipid and barrier support.
Independently dermatologically tested by AITEX.
10/10 negative reactions in the independent dermatological study.
Irritation Index: 0.0.
NON-IRRITATING under the study conditions.
VERY GOOD SKIN COMPATIBILITY in sensitive skin.
Currently undergoing a clinical trial at Hospital General Universitario de Valencia.
Clinical trial results are pending.
Technology Features
RX Cream uses a multi-pathway formulation strategy specifically conceived for radiotherapy-stressed skin.
Melatonin forms the antioxidant core of the formula, complemented by tocopherol. A lipid system incorporating linoleic acid, linolenic acid, oleic acid, palmitic acid, lecithin and olive-derived lipids provides emollient and lipid-replenishing care, while betaine, glycerin, propylene glycol and propanediol provide complementary hydration and skin-conditioning support.
Rather than targeting a single manifestation of compromised skin, the formulation addresses multiple dermocosmetic needs associated with radiotherapy-stressed skin, including oxidative stress, dehydration, lipid depletion, barrier impairment, dryness and discomfort.
Its technological development extends into clinical research, with RX Cream currently undergoing a hospital-based clinical trial in the context of radiotherapy-exposed skin.
Its packaging incorporates recycled and recyclable plastic, a metal-free dispensing valve and recycled cardboard secondary packaging without plastic components
Website and/or Social Media Channels + Editorial pitch
www.iuver-institute.com
@iuverinstitute
Ingredients & Formulation (INCI List Mandatory otherwise you will be disqualified), Olfactive Composition & Sensory Experience (mandatory for fragrance)
Aqua, Propylene Glycol, Propanediol, Triethylhexanoin, Stearic Acid, Batyl Alcohol, Caprylic/Capric Glycerides, Melatonin, Hydrogenated Ethylhexyl Olivate, Polyacrylate Crosspolymer-11, Betaine, Cetyl Alcohol, Hydrogenated Olive Oil Unsaponifiables, Glycerin, Linolenic Acid, Linoleic Acid, Lecithin, Palmitic Acid, Oleic Acid, Caprylic/Capric Triglyceride, Salicylic Acid, Sodium Hydroxide, Tetrasodium Glutamate Diacetate, Tocopherol, Benzyl Alcohol, Sorbic Acid. Lista de ingredientes_F022-001-…
Hero Ingredients & Formulation
Melatonin forms the antioxidant core of IUVER MEDICA RX Cream and represents the scientific signature of the formulation.
Linoleic acid, linolenic acid, oleic acid, palmitic acid, lecithin and olive-derived lipids form a complementary lipid system providing emollient and lipid-replenishing care designed to support compromised skin.
Betaine, glycerin, propylene glycol and propanediol contribute humectant and skin-conditioning properties, supporting hydration and comfort.
Tocopherol complements melatonin within the antioxidant strategy.
Together, these ingredients create a multi-pathway formulation combining antioxidant support, hydration, lipid replenishment, emollience and barrier care for radiotherapy-stressed skin
How to use it
Apply an appropriate amount to clean, dry skin and spread gently without excessive friction.
Use as part of the supportive skincare routine for skin undergoing or recovering from radiotherapy.
Adapt application frequency to the condition of the skin and recommendations of the treating healthcare team.
Follow the radiotherapy unit’s instructions regarding application timing before treatment sessions.
Do not apply to open wounds or severely damaged skin unless specifically advised by the healthcare professional.
Sustainability List of Certifications
Recycled cardboard outer box.
Plastic-free secondary packaging.
Primary container manufactured from recycled and recyclable plastic.
Metal-free dispensing valve, designed to facilitate recycling of the complete primary container.
Packaging design prioritises material compatibility and recyclability.
Reduced material complexity facilitates end-of-life waste separation.
No unnecessary plastic components in the secondary packaging.
Market positioning & distribution countries
Pre-launch dermocosmetic innovation — not yet commercially available.
Specifically developed for the particular needs of radiotherapy-stressed skin.
Positioned within supportive oncology skincare, at the intersection of dermatological science and advanced dermocosmetics.
Represents the most clinically focused development within the IUVER MEDICA range.
Currently undergoing a clinical trial at Hospital General Universitario de Valencia.
Commercial launch planned for November 2026.
Future distribution is intended through specialist pharmacies, medical and oncology-related channels, clinics and selected dermocosmetic partners.
International commercialization will follow the product’s clinical and commercial launch strategy.
Certifications & Patents
Independent dermatological safety assessment conducted by AITEX — Report 2025LP0148.
48-hour occlusive patch + Tape Stripping under dermatologist supervision.
10 sensitive-skin volunteers completed the study.
10/10 negative reactions.
Irritation Index (IR): 0.0.
NON-IRRITATING under the study conditions.
VERY GOOD SKIN COMPATIBILITY.
Authorized claim: “Dermatologically tested.”
Currently undergoing a clinical trial at Hospital General Universitario de Valencia in the context of radiotherapy-exposed skin.
Clinical trial status: ONGOING — results pending.
Developed in accordance with applicable European cosmetic regulatory requirements
时间表
2026年7月27日
平台开放
2026年10月07日
截止报名
2026年10月27日
公布入围名单
2026年11月11日
颁奖典礼公布专业大奖得奖者